ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,477.90
0.16%
Dow Jones
39,127.80
0.04%
US Dollar vs MXN
18.3401
1.18%
Brent Oil
84.485
0.36%
Bitcoin
60,979.43
-1.35%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Bicycle Therapeutics PLC (BCYC)

  7. Bicycle Therapeutics PLC (BCYC) Noticias

BCYC

Bicycle Therapeutics (BCYC)

Bicycle Therapeutics PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:BCYC
FechaHoraFuenteTítuloSímboloCompañía
18/06/202415:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCYCBicycle Therapeutics PLC
18/06/202415:14Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:BCYCBicycle Therapeutics PLC
03/06/202406:00Business WireBicycle Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:BCYCBicycle Therapeutics PLC
23/05/202416:05Business WireBicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual MeetingNASDAQ:BCYCBicycle Therapeutics PLC
23/05/202406:00Business WireBicycle Therapeutics Announces $555 Million Private Placement Equity FinancingNASDAQ:BCYCBicycle Therapeutics PLC
02/05/202406:00Business WireBicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial ResultsNASDAQ:BCYCBicycle Therapeutics PLC
24/04/202409:05Business WireBicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual MeetingNASDAQ:BCYCBicycle Therapeutics PLC
02/04/202406:00Business WireBicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:BCYCBicycle Therapeutics PLC
05/03/202415:35Business WireBicycle Therapeutics to Present at the AACR Annual Meeting 2024NASDAQ:BCYCBicycle Therapeutics PLC
21/02/202415:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCYCBicycle Therapeutics PLC
21/02/202415:40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BCYCBicycle Therapeutics PLC
20/02/202407:38Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BCYCBicycle Therapeutics PLC
20/02/202406:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BCYCBicycle Therapeutics PLC
20/02/202406:05Business WireBicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:BCYCBicycle Therapeutics PLC
14/02/202415:08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BCYCBicycle Therapeutics PLC
07/02/202406:00Business WireBicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:BCYCBicycle Therapeutics PLC
03/01/202415:35Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BCYCBicycle Therapeutics PLC
14/12/202306:00Business WireBicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D DayNASDAQ:BCYCBicycle Therapeutics PLC
30/11/202306:00Business WireBicycle Therapeutics to Host R&D Day on December 14NASDAQ:BCYCBicycle Therapeutics PLC
02/11/202306:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BCYCBicycle Therapeutics PLC
02/11/202306:00Business WireBicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D DayNASDAQ:BCYCBicycle Therapeutics PLC
19/10/202306:00Business WireBicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder CancerNASDAQ:BCYCBicycle Therapeutics PLC
19/10/202303:00GlobeNewswire Inc.Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive DirectorNASDAQ:BCYCBicycle Therapeutics PLC
11/09/202310:08Dow Jones NewsBicycle Therapeutics Shares Rise 8% After Continuation of BT8009 DevelopmentNASDAQ:BCYCBicycle Therapeutics PLC
11/09/202306:00Business WireBicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder CancerNASDAQ:BCYCBicycle Therapeutics PLC
05/09/202306:00Business WireBicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:BCYCBicycle Therapeutics PLC
03/08/202305:59Business WireBicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:BCYCBicycle Therapeutics PLC
18/07/202306:00Business WireBicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:BCYCBicycle Therapeutics PLC
13/07/202315:17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BCYCBicycle Therapeutics PLC
12/07/202321:23Business WireBicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary SharesNASDAQ:BCYCBicycle Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:BCYC

Su Consulta Reciente

BIT
P1JHH2
BNP Paribas Issuance
GDAX
MUSDUSD
mStable USD
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados